Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds RSS Feed PharmiWeb Candidate Blog RSS Feed PharmiWeb Client Blog


Press Release

Natera to Present at the Baird 2016 Global Healthcare Conference

Posted on: 02 Sep 16

PR Newswire

SAN CARLOS, Calif., Sept. 2, 2016

SAN CARLOS, Calif., Sept. 2, 2016 /PRNewswire/ -- Natera, Inc. (Nasdaq: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today announced that it will present at the Baird 2016 Global Healthcare Conference in New York, NY on Thursday, September 8, 2016 at 7:55 a.m. ET. Steve Chapman, Chief Commercial Officer of Natera, will discuss the Company's financial results, business activities and financial outlook. Natera will offer a live audio webcast of the presentation that may be accessed on the Investor Relations section of the Company's website at . A replay of the webcast also will be archived and available for 30 days after the presentation.

About Natera

Natera is a leading genetic testing company that develops and commercializes non-invasive methods for analyzing DNA. The mission of the company is to transform the diagnosis and management of genetic disease. In pursuit of that mission, Natera operates a CAP-accredited laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA) in San Carlos, CA, and it currently offers a host of proprietary genetic testing services primarily to OB/GYN physicians and fertility centers, as well as to genetic laboratories through its direct sales force, laboratory distribution partners, and licensees that can run tests in their own laboratories and have the data analyzed through Natera's cloud-based Constellation™ software system. Tests include the Spectrum® pre-implantation genetic test for embryo selection during IVF; the Anora® miscarriage test to understand the genetic causes of a pregnancy loss; the Horizon™ carrier screen to detect inherited mutations; and the Panorama® non-invasive prenatal test (NIPT) to screen for common chromosomal anomalies in a fetus as early as nine weeks of gestation. Each test described has been developed and its performance characteristics determined by the CLIA-certified laboratory performing the test. These tests have not been cleared or approved by the U.S. Food and Drug Administration (FDA). Although FDA does not currently clear or approve laboratory-developed tests in the U.S., certification of the laboratory is required under CLIA to ensure the quality and validity of the tests.

Natera is also applying its unique technologies to develop non-invasive screening and diagnostic tools for earlier detection and improved treatment of cancer. These tests have not been cleared or approved by the U.S. Food and Drug Administration.

Natera, Inc.
Mike Brophy, Investor Relations, 650-249-9091 x 1471

Logo -


To view the original version on PR Newswire, visit:

SOURCE Natera, Inc.

PR Newswire

Last updated on: 02/09/2016

Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.